Search Results - immune+checkpoint+blockade

3 Results Sort By:
Targeting Serotonin Transporter (SERT) for Cancer Immunotherapy (UCLA Case No. 2024-204)
UCLA researchers in the Department of Microbiology Immunology and Molecular Genetics have unveiled a novel therapeutic strategy utilizing SSRIs for solid cancer immunotherapy. BACKGROUND: Immunotherapy has become a highly effective method to combat cancer that enhances a patient’s immune system to attack tumors with high specificity. For instance,...
Published: 6/18/2024   |   Inventor(s): Lili Yang
Keywords(s): Cancer, Immune checkpoint blockade, immune checkpoint inhibitors, Immunotherapy, selective serotonin reuptake inhibitors (SSRIs), serotonin, solid tumors, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Strategies to Detect, Prevent and Reverse Acquired Resistance to Immune Checkpoint Blockade Therapy (UCLA Case No. 2024-085)
UCLA researchers in the Department of Medicine have uncovered novel mechanism of acquired resistance against immune checkpoint blockade therapy in melanoma patients. BACKGROUND: Immune checkpoint blockade (ICB) therapy is a type of cancer immunotherapy that targets immune system components in order to reactivate immune cells to combat tumor cells....
Published: 5/8/2024   |   Inventor(s): Roger Lo
Keywords(s): acquired resistance, Apoptosis, Cancer, Cancer Immunotherapy, Immune checkpoint blockade, Immunotherapy, Melanoma, T Cell
Category(s): Therapeutics > Oncology, Therapeutics > Immunology And Immunotherapy
Antitumor activity of NKTR-214 alone or in combination with anti-PD-1 therapy in tumors resistant to anti-PD-1 (UCLA Case No. 2019-254)
UCLA researchers have discovered a therapy for anti-PD-1 resistant tumors in colon carcinoma patients. A small molecule therapeutic alone or in combination with immune-checkpoint blockade (ICB) therapy exhibits tumor remission even in sublines with mutated signalling pathways that have rendered them ICB resistant. BACKGROUND: Immunotherapy, the...
Published: 2/15/2024   |   Inventor(s): Antoni Ribas
Keywords(s): Colon carcinoma, Immune checkpoint blockade, Immunotherapy, Oncology, Oncology (Small Molecules, Peptides and Antibodies), PD-1, PD-L1, Resistant tumors, Signaling pathways, Small molecule therapeutics, Tumor
Category(s): Life Science Research Tools, Therapeutics > Oncology > Oncology Immunotherapy, Therapeutics > Oncology > Oncology (Small Molecules)